Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A multicenter randomized phase II/III trial of preoperative versus postoperative chemotherapy with XELOX plus bevacizumab in patients with resectable colorectal liver metastasis.

ABSTRACT: Interventions: A: Within 56 days after surgery, patients receive infusional oxaliplatin and oral capecitabine. Patients receive infusional bevacizumab as from second course. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. B: Patients receive infusional oxaliplatin, bevacizumab and oral capecitabine. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients do not receive bevacizumab at last course. Within 56 days after chemotherapy, patients receive surgery. Primary outcome(s): Treatment compliance (phase II) Progression-free survival (phase III) Study Design: Parallel Randomized

DISEASE(S): Resectable Liver Metastasis From Colorectal Cancer

PROVIDER: 2619239 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Randomized study of hepatectomy+mFOLFOX6 vs. hepatectomy alone for liver metastasis of colorectal cancer (JCOG0603)

Project description:Interventions: A: Live resection B: At 56 to 84 days after hepatectomy, patients receive 2-hour infusion of oxaliplatin IV and l-leucovorin on day 1 followed by fluorouracil (5-FU) bolus and 46-hour infusion on day 1. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. Primary outcome(s): Treatment compliance at 9 courses after beginning mFOLFOX6 (phaseII) Disease-free survival (phaseIII) Study Design: Parallel Randomized

| 2616158 | ecrin-mdr-crc

JCOG0603: Randomized study of hepatectomy+mFOLFOX6 vs. hepatectomy alone for liver metastasis of colorectal cancer

| 2614114 | ecrin-mdr-crc

Liver resection after chemotherapy for liver only metastasis from colorectal cancer

Project description:Interventions: Chemotherapy with modified FOLFOX6 plus BV(bevacizumab). Treatment repeats every 14 days for up to 6 courses (5 courses for BV) in the absence of disease progression or unacceptable toxicity. Liver resection (if possible, 4 to 8 weeks after modified FOLFOX6 plus BV) Primary outcome(s): Curative resection rate (R0 resection rate) [in all subjects] Study Design: Single arm Non-randomized

| 2617582 | ecrin-mdr-crc

Multicenter phase II trial of mFOLFOX6 with cetuximab as active chemotherapy regimen for liver metastases inappropriate for curative resection in EGFR positive and KRAS wild type colorectal cancer

Project description:Interventions: Chemotherapy with modified FOLFOX6 plus cetuximab. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Liver resection (if possible, 6 weeks after modified FOLFOX6 plus cetuximab) Primary outcome(s): R0 resection rate (Curative resection rate) Study Design: Single arm Non-randomized

| 2620128 | ecrin-mdr-crc

A phase I/II study of hepatic arterial 5-flurouracil (5FU) combined with intravenous irinotecan hydrochloride (CPT-11) for metastatic colorectal cancer isolated in the liver. (JCOG 0208-DI)

Project description:Interventions: Patients undergo implantation of hepatic arterial catheter and port system percutaneously, and then, receive hepatic arterial administration of 5-fluorouracil at day 1,8, and 15 followed by intravenous administration of irinotecan hydrochloride at day 1 and 15. Treatment repeats every 4 weeks for 5 courses in the absence of disease progression or unacceptable toxicity. Primary outcome(s): Adverse events Study Design: Single arm Non-randomized

| 2609482 | ecrin-mdr-crc

A Multicenter Phase II trial of TS-1/oxaliplatin (SOX) +bevacizumab in patients with unresectable advanced/metastatic colorectal cancer (HiSCO-02)

Project description:Interventions: Patients receive infusional oxaliplatin, bevacizumab, and oral TS-1 every 21 days. Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2620419 | ecrin-mdr-crc

Phase I study of XELOXIRI(CPT-11,L-OHP, capecitabine) with Bevacizumab in patients with unresectable advanced/metastatic colorectal cancer

Project description:Interventions: Patients receive infusional CPT-11,L-OHP, bevacizumab, and oral capecitabine every 21 days. Primary outcome(s): Safety Study Design: Single arm Non-randomized

| 2620878 | ecrin-mdr-crc

Conversion therapy of Cetuximab plus FOLFIRI followed by Bevacizumab plus mFOLFOX6 in patients with liver metastatic colorectal cancer

Project description:Interventions: Chemotherapy with Cetuximab plus FOLFIRI followed by Bevacizumab plus mFOLFOX6. Treatment repeats every 14 days for up to 12 courses (6 courses for Cetuximab plus FOLFIRI and 6 courses for Bevacizumab plus mFOLFOX6) . Liver resection (if possible) Primary outcome(s): Liver resection rate after chemotherapy with Bevacizumab plus mFOLFOX6(R0/R1) Study Design: Single arm Non-randomized

| 2620139 | ecrin-mdr-crc

A phase II Study of Useful therapeutic strategy for metastatic Colorectal Cancer to Evaluate Oxaliplatin Stop and Go in SOX+Bmab

Project description:Interventions: TS-1 80mg/m2/day (day1-14) and Oxaliplatin 130mg/m2 (day1) and Bevacizumab 7.5mg/kg (day1) every 21 days for 4 courses followed by TS-1 80mg/m2/day (day1-14) and Bevacizumab 7.5mg/kg (day1) every 21 days for 8 courses. And next, administer until PD the same SOX+Bmab regimen. Primary outcome(s): Progression-free Survival Study Design: Single arm Non-randomized

| 2622829 | ecrin-mdr-crc

Randomized phase III trial comparing adjuvant S-1 to capecitabine in stage III colorectal cancer (JCOG0910, CRC Adj-CAPS)

Project description:Interventions: A: capecitabine. Patients in this group receive 8 courses of oral capecitabine, at a dose of 1,250 mg/m2 twice daily for 14 days every 21 days. B: S-1. Patients in this group receive 4 courses of oral S-1, at a dose of 40 mg/m2 twice daily for28 days every 42 days. Primary outcome(s): Disease-free survival Study Design: Parallel Randomized

| 2618731 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data